Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Daiichi Sankyo Company, Limited (4568.T)
Tokyo, JP
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively involved in the research, development, manufacturing, importation, marketing, and distribution of a diverse array of medicinal products worldwide. Its extensive product lineup addresses numerous therapeutic areas. In oncology, key offerings include trastuzumab deruxtecan, an anti-HER2 antibody drug conjugate, alongside treatments like Gefitinib for malignant tumors, Bicalutamide for prostate cancer, and Tamoxifen, an anti-breast cancer agent. For pain management, the company provides mirogabalin and loxoprofen (an anti-inflammatory analgesic). Diabetes treatments feature teneligliptin/canagliflozin and teneligliptin, with colesevelam serving dual purposes for hypercholesterolemia and type 2 diabetes. Other notable prescription drugs include lacosamide (an anti-epileptic), prasugrel (an antiplatelet), denosumab (for osteoporosis and bone disorders), edoxaban (an anticoagulant), esomeprazole (for ulcer treatment), memantine (for Alzheimer's disease), and laninamivir (for influenza). The company also supplies olmesartan (an antihypertensive), levofloxacin (an antibacterial), pravastatin (for hypercholesterolemia), Silodosin (for dysuria), and ferric carboxymaltose/iron sucrose injections for anemia. Beyond prescription medications, Daiichi Sankyo markets popular consumer health brands such as Lulu (a combination cold remedy), Loxonin S (an antipyretic/anti-inflammatory painkiller), Transino (for melasma and skin improvement), Minon (skincare), and the oral care lines Breath Labo and Clean Dental. The company further contributes to public health with various vaccines, including adsorbed cell culture-derived influenza, influenza HA, measles-rubella combined, and mumps vaccines. Its operations also extend beyond human pharmaceuticals to include veterinary drugs, cosmetics, medical equipment, food products, drinking water, and the production of active pharmaceutical ingredients (APIs) and intermediates. Daiichi Sankyo is collaborating with Guardant Health on the development of Guardant360 CDx, a companion diagnostic for Enhertu, specifically for advanced metastatic non-small cell lung cancer. Founded in 1899, the company is headquartered in Tokyo, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.46% | +2.85% | -0.22% | -7.22% | -20.42% | -22.79% | -22.50% | -41.71% | +1.15% | +220.77% | +523.21% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 11 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - General: +6.6%+12.6% ★ Q1'26: +13.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%-9.9% Q1'26: -50.1% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+3.2% Q1'26: -0.8% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+9.8% Q1'26: -3.7% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+13.5% ★ Q1'26: -3.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%-2.4% ★ Q1'26: -2.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×1.06× ★ Q1'26: -77.05× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 12 Rev. Ana. 13 EPS Ana. |
Mar 2027 11 Rev. Ana. 16 EPS Ana. |
Mar 2028 14 Rev. Ana. 14 EPS Ana. |
Mar 2029 11 Rev. Ana. 9 EPS Ana. |
Mar 2030 7 Rev. Ana. 3 EPS Ana. |
Mar 2031 7 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
919.37B
est: 940.36B (-2.2%)
|
986.45B
est: 983.61B (+0.3%)
|
955.12B
est: 945.03B (+1.1%)
|
960.20B
est: 953.46B (+0.7%)
|
929.72B
est: 916.19B (+1.5%)
|
981.79B
est: 974.72B (+0.7%)
|
962.52B
est: 968.33B (-0.6%)
|
1.04T
est: 1.04T (+0.9%)
|
1.28T
est: 1.27T (+1.0%)
|
1.60T
est: 1.69T (-5.1%)
|
1.89T
est: 1.85T (+1.9%)
|
2.13T
2.10T – 2.22T
+15.3% YoY
|
2.36T
2.27T – 2.70T
+10.8% YoY
|
2.56T
2.28T – 3.59T
+8.3% YoY
|
2.83T
2.80T – 2.86T
+10.5% YoY
|
3.26T
3.01T – 4.15T
+15.1% YoY
|
2.96T
2.74T – 3.77T
-9.1% YoY
|
| EBITDA |
116.45B
est: 142.05B (-18.0%)
|
174.72B
est: 148.59B (+17.6%)
|
136.30B
est: 142.76B (-4.5%)
|
122.96B
est: 144.03B (-14.6%)
|
129.88B
est: 138.40B (-6.2%)
|
191.41B
est: 147.24B (+30.0%)
|
121.18B
est: 146.28B (-17.2%)
|
131.27B
est: 156.39B (-16.1%)
|
169.72B
est: 191.23B (-11.3%)
|
271.13B
est: 254.85B (+6.4%)
|
380.57B
est: 279.66B (+36.1%)
|
322.35B
317.39B – 335.62B
+15.3% YoY
|
357.17B
343.28B – 408.23B
+10.8% YoY
|
386.90B
343.89B – 541.79B
+8.3% YoY
|
427.64B
422.89B – 432.39B
+10.5% YoY
|
492.06B
454.71B – 627.27B
+15.1% YoY
|
447.19B
413.25B – 570.07B
-9.1% YoY
|
| EBIT |
74.42B
est: 96.54B (-22.9%)
|
130.41B
est: 100.98B (+29.2%)
|
88.93B
est: 97.02B (-8.3%)
|
76.28B
est: 97.88B (-22.1%)
|
83.71B
est: 94.06B (-11.0%)
|
138.80B
est: 100.06B (+38.7%)
|
63.80B
est: 99.41B (-35.8%)
|
73.03B
est: 106.28B (-31.3%)
|
101.93B
est: 129.96B (-21.6%)
|
211.48B
est: 173.19B (+22.1%)
|
311.92B
est: 190.05B (+64.1%)
|
219.06B
215.69B – 228.08B
+15.3% YoY
|
242.73B
233.29B – 277.43B
+10.8% YoY
|
262.93B
233.70B – 368.19B
+8.3% YoY
|
290.62B
287.39B – 293.84B
+10.5% YoY
|
334.39B
309.01B – 426.28B
+15.1% YoY
|
303.90B
280.83B – 387.41B
-9.1% YoY
|
| Net Income |
322.12B
est: 59.04B (+445.6%)
|
82.28B
est: 74.21B (+10.9%)
|
53.47B
est: 68.45B (-21.9%)
|
60.28B
est: 55.80B (+8.0%)
|
93.41B
est: 60.74B (+53.8%)
|
129.07B
est: 108.26B (+19.2%)
|
75.96B
est: 57.41B (+32.3%)
|
66.97B
est: 69.26B (-3.3%)
|
109.19B
est: 100.87B (+8.2%)
|
200.73B
est: 229.10B (-12.4%)
|
295.76B
est: 295.87B (0.0%)
|
303.66B
297.41B – 356.34B
+2.6% YoY
|
346.70B
291.88B – 481.06B
+14.2% YoY
|
395.10B
280.66B – 758.31B
+14.0% YoY
|
417.44B
326.78B – 771.51B
+5.7% YoY
|
567.07B
511.11B – 769.63B
+35.8% YoY
|
518.96B
467.75B – 704.35B
-8.5% YoY
|
| SGA |
331.20B
est: 346.60B (-4.4%)
|
328.76B
est: 362.54B (-9.3%)
|
302.48B
est: 348.32B (-13.2%)
|
301.85B
est: 351.43B (-14.1%)
|
277.70B
est: 337.69B (-17.8%)
|
302.32B
est: 359.26B (-15.8%)
|
333.08B
est: 356.91B (-6.7%)
|
358.31B
est: 381.59B (-6.1%)
|
471.22B
est: 466.59B (+1.0%)
|
637.00B
est: 621.80B (+2.4%)
|
731.20B
est: 682.34B (+7.2%)
|
786.50B
774.41B – 818.89B
+15.3% YoY
|
871.46B
837.57B – 996.05B
+10.8% YoY
|
944.00B
839.06B – 1.32T
+8.3% YoY
|
1.04T
1.03T – 1.05T
+10.5% YoY
|
1.20T
1.11T – 1.53T
+15.1% YoY
|
1.09T
1.01T – 1.39T
-9.1% YoY
|
| EPS |
152.52
est: 31.12 (+390.2%)
|
39.79
est: 39.11 (+1.7%)
|
26.54
est: 36.08 (-26.4%)
|
30.44
est: 29.41 (+3.5%)
|
48.07
est: 32.01 (+50.2%)
|
66.40
est: 57.05 (+16.4%)
|
39.17
est: 30.26 (+29.5%)
|
34.94
est: 36.50 (-4.3%)
|
56.96
est: 53.16 (+7.1%)
|
104.69
est: 119.53 (-12.4%)
|
155.96
est: 126.80 (+23.0%)
|
166.56
156.74 – 187.80
+31.4% YoY
|
188.21
153.82 – 253.53
+13.0% YoY
|
218.92
147.91 – 399.64
+16.3% YoY
|
238.33
172.22 – 406.60
+8.9% YoY
|
298.85
269.36 – 405.61
+25.4% YoY
|
273.50
246.51 – 371.20
-8.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-01 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-15 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sunao Manabe | Executive Chairperson | 302M | male |
| Hiroyuki Okuzawa | President, Chief Executive Officer & Representative Director | 215M | male |
| Joji Nakayama | Senior Adviser | 154M | male |
| Kentaro Asakura | Corporate Officer and Head of Corporate Communications Dept, Global Corporate Planning & Mngmt | — | — |
| Kentaro Murakawa | President of Daiichi Sankyo Espha Co., Ltd. | — | male |
| Koji Ogawa | Senior Exe. Off., Head of Corporate Planning & Mgt. and Chief Financial Officer | — | male |
| Marielle Cohard-Radice | Global Head of Development | — | female |
| Matt Allegrucci | Head of Global Compliance & Risk Management and Chief Compliance Officer | — | — |
| Naoto Tsukaguchi | Senior Executive Officer, Head of Global Legal & IP, GC | — | — |
| Stuart Mackey | Global Head of Business Development | — | male |
| Takashi Matsumoto | Sr. Exec Ofcr, Chief Corp Affairs Ofcr, Head of Global Corp Affairs & HR, CHRO & Director | — | male |
| Tetsuya Ohira | Corporate Officer, Head of Business Transformation & CTO | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4568.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
